checkAd
    Startseite > Aktien > VistaGen Therapeutics > Nachrichten
    VistaGen Therapeutics Aktie
    0,0995
     
    USD
    -25,75 %
    -0,0345 USD
    Letzter Kurs 07.06.23 Nasdaq
    0,0990
     
    USD
    39.900 STK
    Geldkurs 06.06.23
    0,0995
     
    USD
    28.800 STK
    Briefkurs 06.06.23
    ISIN: US92840H2022 · WKN: A2AJU8 · SYM: VTGN · USA

    Neueste Nachrichten

    Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
    25.04.24 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
    09.04.24 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
    01.04.24 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen to Present at Stifel 2024 Virtual CNS Days
    11.03.24 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen to Present at TD Cowen 44th Annual Health Care Conference
    28.02.24 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
    13.02.24 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
    06.02.24 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
    27.12.23 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
    09.11.23 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen to Present at Stifel 2023 Healthcare Conference
    08.11.23 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
    07.11.23 · Business Wire (engl.) · VistaGen Therapeutics
    Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
    06.11.23 · Business Wire (engl.) · VistaGen Therapeutics